

Pressrelease June 10, 2003

Orexo Pharmaceuticals – pathmaker in therapeutics

Orexo AB is the new name of Diabact AB, the Swedish pharmaceutical company that is based on innovative drug delivery and pharmaceutical development. As of June 10, 2003 Diabact formally changes its name to Orexo.

Orexo utilizes its proprietary technology platforms to develop patented products with significant patient advantages. Orexo has a product on the market and several projects in various stages of development in a number of therapeutic areas.

“We combine clinical insight with a high level of competence in drug delivery. This leaves Orexo in the unique position of being able to deliver products to the market in a significantly shorter time than traditional pharmaceutical companies.” We are a progressive and fast growing company and ambitious to become a leader in our niche. The name Diabact was too closely linked to our first product and diagnostic tests. We saw the change of name to Orexo, the strengthening of the organisation through recruitment, and a greater strategic focus as natural steps in our ambition to become a significant global company in pharmaceutical development”, said Björn Forsman, Orexo’s Chief Executive Officer.

For more information, please contact

Björn Forsman, CEO Orexo AB

+46 (0)18 780 88 00, +46(0)70 531 88 28, e-mail: bjorn.forsman@orexo.se

Orexo AB (publ) is a Swedish pharmaceutical company established in 1995 and based in Uppsala. Orexo develops, documents and registers patented pharmaceutical products based on innovative and proprietary drug formulations. This is done through in-house development, licensing or co-development with partners.

Orexo currently runs a number of pharmaceutical projects with considerable market potential, for instance within the pain control and the gastro-intestinal area. Rapinyl[®], one of the products in development for the management of acute pain, is in clinical phase II. It is now being documented for cancer breakthrough pain. Rapinyl[®] is based on the company’s patented technical platforms with fast dissolving tablets for rapid pain relief. The Japanese development and marketing rights for Rapinyl[®] was licensed to Kyowa Hakko Kogyo Co. Ltd in January 2003.

www.orexo.com